- Page 1 and 2: 2010 Annual Report CIBERDEM Centro
- Page 4 and 5: Letter from the Scientific Director
- Page 6 and 7: Contents Prologue Research results
- Page 8 and 9: Research results Publications In 20
- Page 10 and 11: Project management Introduction The
- Page 12 and 13: Training programme Introduction The
- Page 14 and 15: Outreach activities CIBERDEM Fundra
- Page 16 and 17: More about CIBERDEM The Centro de I
- Page 18 and 19: Human Resources In 2010, CIBERDEM h
- Page 20 and 21: Transversal projects Di@bet.es Stud
- Page 22 and 23: Di@bet.es Study Introduction Attemp
- Page 24 and 25: CIBERDEM Projects Introduction CIBE
- Page 26 and 27: girls (girls born small for gestati
- Page 28 and 29: Biobank Introduction and objectives
- Page 30 and 31: Metabolomics Platform Introduction
- Page 34 and 35: In 2010, we deeply regret the loss
- Page 36 and 37: Endocrinology, 151, 3084-3094 (2010
- Page 38 and 39: Ministerio de Ciencia e Innovación
- Page 40 and 41: Garcia-Guerra L, Nieto-Vazquez I, V
- Page 42 and 43: Comparative gene expression profili
- Page 44 and 45: Private funds Mejora de la predicci
- Page 46 and 47: differentiation and protection agai
- Page 48 and 49: Private funds The role of Amylin in
- Page 50 and 51: Subjects with early-onset type 2 di
- Page 53 and 54: Area 2 Dyslipidaemia, metabolic syn
- Page 55 and 56: The Eicosanoid Research Division In
- Page 57 and 58: Metabolic disease and cardiovascula
- Page 59 and 60: Principal Investigator: Escolà Gil
- Page 61 and 62: the population-based Hortega study
- Page 63 and 64: Diabetes, Obesity and Reproductive
- Page 65 and 66: Meta-analysis of the mean differenc
- Page 67 and 68: Publications* Original articles A s
- Page 69 and 70: Clinical practice guidelines Insuli
- Page 71 and 72: -The impact of nutrition on metabol
- Page 73 and 74: An international multicentre, rando
- Page 75 and 76: BMC Med Genet, 11, 148 (2010) IF: 2
- Page 77 and 78: Diabetes and Metabolism Research Gr
- Page 79 and 80: National projects Impacto del uso d
- Page 81 and 82: Name of the participants: A Lecube
- Page 83 and 84:
from the prospective Pizarra study
- Page 85 and 86:
INGENFRED: 2009-2010 Coordinator: F
- Page 87 and 88:
RM, Laguna JC, Vázquez-Carrera M E
- Page 89 and 90:
Thromb Haemost, 103, 780-787 (2010)
- Page 91 and 92:
Area 3 Islet dysfunction, destructi
- Page 93 and 94:
Endocrinology and metabolism Depart
- Page 95 and 96:
Brain glucose sensor, satiety contr
- Page 97 and 98:
Caracterización del mecanismo neur
- Page 99 and 100:
Publications* Original articles Chr
- Page 101 and 102:
Patent application number: EP101683
- Page 103 and 104:
IF: 8.505 first decile. With other
- Page 105 and 106:
diabetes and new therapeutic strate
- Page 107 and 108:
Bristol-Myers Squibb, CEIC 08/47: 2
- Page 109 and 110:
terapéutica que la contiene y sus
- Page 111 and 112:
MA, Xu X, Van de Casteele M, Skoudy
- Page 113 and 114:
-Epigenetic regulation of adipogene
- Page 115 and 116:
IREVAS: 2009-2010 Coordinator: Manu
- Page 117 and 118:
Dev Biol, 346, 346-355 (2010) IF: 4
- Page 119 and 120:
Group of Research into Diabetes and
- Page 121 and 122:
Determinants of insulin resistance
- Page 123 and 124:
Environ Health Perspect, 118, 1243-
- Page 125 and 126:
Metabolic and molecular disturbance
- Page 127 and 128:
CIBERDEM Biobank Nodes: A Novials,
- Page 129:
Research grants National project A
- Page 132 and 133:
Principal Investigator index Álvar
- Page 134 and 135:
Publications index* A map of open c
- Page 136 and 137:
dDOR is an EcR coactivator that for
- Page 138 and 139:
Morales-Suárez-Varela MM, Mansego
- Page 140 and 141:
Obesity and insulin resistance-rela
- Page 142 and 143:
Reduced insulin secretion in protei
- Page 144 and 145:
Treatment of polycystic ovary syndr
- Page 146:
CIBERDEM, the Spanish Biomedical Re